NKGen Biotech Inc. (NKGN) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
3001 DAIMLER ST, SANTA ANA, CA 92705 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 26 | 635 | 1,723 | |||
| Cash and cash equivalents | 26 | 635 | 1,723 | |||
| Restricted cash and investments | 250 | |||||
| Receivables | 26 | |||||
| Prepaid expense | 1,565 | 243 | 813 | |||
| Other current assets | 16 | |||||
| Other undisclosed current assets | 47 | |||||
| Total current assets: | 1,930 | 878 | 2,535 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | ||||||
| Property, plant and equipment | 14,459 | |||||
| Asset, held-in-trust | 173,488 | 171,656 | ||||
| Other undisclosed noncurrent assets | 92 | |||||
| Total noncurrent assets: | 14,551 | 173,488 | 171,656 | |||
| TOTAL ASSETS: | 16,481 | 174,366 | 174,191 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 13,395 | 2,622 | 1,708 | |||
| Accounts payable | 11,040 | 177 | 52 | |||
| Accrued liabilities | 1,360 | 2,444 | 1,656 | |||
| Other undisclosed accounts payable and accrued liabilities | 995 | |||||
| Debt | 9,991 | |||||
| Derivative instruments and hedges, liabilities | 15,804 | |||||
| Other liabilities | 262 | |||||
| Other undisclosed current liabilities | 224 | 185 | ||||
| Total current liabilities: | 39,452 | 2,846 | 1,893 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 9,930 | |||||
| Long-term debt, excluding current maturities | 9,930 | |||||
| Liabilities, other than long-term debt | 25,792 | |||||
| Deferred income tax liabilities | 33 | |||||
| Operating lease, liability | ||||||
| Derivative instruments and hedges, liabilities | 25,759 | |||||
| Other undisclosed noncurrent liabilities | 2,527 | 11,578 | ||||
| Total noncurrent liabilities: | 35,722 | 2,527 | 11,578 | |||
| Total liabilities: | 75,174 | 5,373 | 13,471 | |||
| Equity | ||||||
| Equity, attributable to parent, including: | (58,693) | (4,171) | (10,895) | |||
| Common stock | 2 | 0 | ||||
| Common stock, share subscribed but unissued, subscriptions receivable | (17,792) | |||||
| Additional paid in capital | 121,727 | |||||
| Accumulated deficit | (162,130) | (4,171) | (10,895) | |||
| Receivable from shareholders or affiliates for issuance of capital stock | (500) | |||||
| Other undisclosed equity, attributable to parent | 0 | |||||
| Other undisclosed equity | 173,164 | 171,615 | ||||
| Total equity: | (58,693) | 168,993 | 160,720 | |||
| TOTAL LIABILITIES AND EQUITY: | 16,481 | 174,366 | 174,191 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues | 500 | ||||
| Loss on disposition of assets for financial service operations | |||||
| Net investment income | 500 | ||||
| Gross profit: | 500 | ||||
| Operating expenses | (29,746) | (2,391) | (2,215) | ||
| Other undisclosed operating income (loss) | (500) | (349) | (294) | ||
| Operating loss: | (29,746) | (2,740) | (2,508) | ||
| Nonoperating income (expense) | 120 | 7,727 | 1,518 | ||
| Investment income, nonoperating | 2,401 | 41 | |||
| Other nonoperating income (expense) | 120 | ||||
| Interest and debt expense | (745) | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (30,371) | 4,987 | (991) | ||
| Other undisclosed loss from continuing operations before income taxes | (52,576) | ||||
| Income (loss) from continuing operations before income taxes: | (82,947) | 4,987 | (991) | ||
| Income tax expense | (7) | (438) | |||
| Other undisclosed loss from continuing operations | |||||
| Income (loss) from continuing operations: | (82,954) | 4,548 | (991) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (991) | |
| Net income (loss): | (82,954) | 4,548 | (991) | ||
| Other undisclosed net loss attributable to parent | |||||
| Net income (loss) attributable to parent: | (82,954) | 4,548 | (991) | ||
| Preferred stock dividends and other adjustments | 2,176 | (17,389) | |||
| Net income (loss) available to common stockholders, diluted: | (82,954) | 6,724 | (18,380) | ||
Comprehensive Income ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net income (loss): | (82,954) | 4,548 | (991) | ||
| Comprehensive income (loss): | (82,954) | 4,548 | (991) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | |||||
| Comprehensive income (loss), net of tax, attributable to parent: | (82,954) | 4,548 | (991) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.